ncRNA basic information
ncRNA ID:
ENSG00000255737
ncRNA Database:
Ensembl
ncRNA Name:
AGAP2-AS1
ncRNA Type:
lncRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-qPCR
ncRNA Target Gene:
MyD88
ncRNA Pathway:
NF-kappaB pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00072 (BTD00098, BIOD00098)
Drug Name:
Trastuzumab
Drug Method:
Trastuzumab-resistant SKBR-3 and BT474 cells were obtained by continuous culture with 5 mg/mL trastuzumab for 6 months. RT-qPCR assay was used to determine the expression of AGAP2-AS1 in tissues and cells. RNA fluorescence in situ hybridization was used to investigate the subcellular location of AGAP2-AS1 in breast cancer cells. Bioinformatic analysis, chromatin immunoprecipitation (ChIP), RNA immunoprecipitation (RIP), western blotting, and immunofluorescence were carried out to verify the regulatory interaction of AGAP2-AS1, CREB-binding protein (CBP), and MyD88. In addition, a series of in vitro assays and a xenograft tumor model were used to analyze the functions of AGAP2-AS1 in breast cancer cells.
Drug Response:
resistant
Cancer basic information
Cancer:
breast cancer
Tissue/Cell:
cell line (SKBR-3 and BT474)
Other information
Title:
SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88.
Journal:
J Exp Clin Cancer Res
Published:
2018
PubMed ID:
30157918